- Home
- DSP vs PBYI Comparison
DSP vs PBYI Comparison
Compare DSP & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- PBYI
- Stock Information
- Founded
- DSP 1999
- PBYI 2010
- Country
- DSP United States
- PBYI United States
- Employees
- DSP N/A
- PBYI N/A
- Industry
- DSP EDP Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- PBYI Health Care
- Exchange
- DSP Nasdaq
- PBYI Nasdaq
- Market Cap
- DSP 220.3M
- PBYI 164.3M
- IPO Year
- DSP 2021
- PBYI N/A
- Fundamental
- Price
- DSP $13.78
- PBYI $3.54
- Analyst Decision
- DSP Strong Buy
- PBYI Strong Buy
- Analyst Count
- DSP 8
- PBYI 1
- Target Price
- DSP $21.75
- PBYI $7.00
- AVG Volume (30 Days)
- DSP 238.8K
- PBYI 306.9K
- Earning Date
- DSP 08-11-2025
- PBYI 07-31-2025
- Dividend Yield
- DSP N/A
- PBYI N/A
- EPS Growth
- DSP N/A
- PBYI 143.51
- EPS
- DSP 0.13
- PBYI 0.77
- Revenue
- DSP $306,484,000.00
- PBYI $232,709,000.00
- Revenue This Year
- DSP $18.36
- PBYI N/A
- Revenue Next Year
- DSP $15.95
- PBYI N/A
- P/E Ratio
- DSP $106.28
- PBYI $4.64
- Revenue Growth
- DSP 30.64
- PBYI 2.68
- 52 Week Low
- DSP $8.70
- PBYI $2.23
- 52 Week High
- DSP $26.33
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- DSP 48.96
- PBYI 58.27
- Support Level
- DSP $12.79
- PBYI $3.26
- Resistance Level
- DSP $13.58
- PBYI $3.65
- Average True Range (ATR)
- DSP 0.57
- PBYI 0.14
- MACD
- DSP 0.06
- PBYI 0.01
- Stochastic Oscillator
- DSP 76.06
- PBYI 82.83
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.